ASCLERA
LOE Approachingpolidocanol
NDAINTRAVENOUSSOLUTION
Approved
Mar 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
4/8 — Partial
ASCLERA (polidocanol) is sclerosing activity [moa]. First approved in 2010.
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ASCLERA (polidocanol) is an intravenous sclerosing agent approved in 2010 for the treatment of varicose veins and venous insufficiency. It works by inducing endothelial damage and fibro-obliteration of targeted veins through direct chemical injury. The drug is indicated for patients with symptomatic varicose veins seeking minimally invasive treatment.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting consolidation of commercial teams and shift toward efficiency-driven roles rather than growth-focused expansion.
Mechanism of Action
Sclerosing Activity
Pharmacologic Class:
Sclerosing Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)
Started Aug 2011
21 enrolled
Varicose Veins
Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Started Dec 2010
279 enrolled
Varicose Veins
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Started Nov 2010
235 enrolled
Varicose Veins
Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Started Sep 2010
117 enrolled
Great Saphenous Vein IncompetenceVisible Varicosities
An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins
Started Jun 2009
16 enrolled
Varicose Veins
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.